GD Biosciences brings PULS Cardiac Test to German market

Global demand for the innovative heart attack risk assessment test prompts further international expansion
(PR NewsChannel) / April 20, 2016 / MANNHEIM, Germany and IRVINE, Calif. 

GD Biosciences CEO Dr. Douglas Harrington M.D. at the German Society of Cardiology's annual meeting in Mannheim

Irvine California-based Global Discovery Biosciences (GD Biosciences), a biotechnology company dedicated to conquering healthcare’s biggest challenges using innovative technology, announced today that its revolutionary PULS Cardiac Test is now available in Germany.

“We’re proud to announce our recent expansion into Germany,” said Dr. Douglas Harrington, M.D., CEO of GD Biosciences. “The PULS Cardiac Test has received significant attention within the medical community as an effective diagnostic and predictive tool that allows physicians to identify patients with subclinical, asymptomatic heart disease, who may otherwise be unaware they are at risk of experiencing an acute cardiac event. Whenever we’re able to expand into a new market, it feels great to know the test will be available to help those who might be missed without it.”

The latest announcement follows a lauded demonstration of the PULS Cardiac Test at the German Society of Cardiology annual meeting in Mannheim where the mission of the Congress is “to reduce the burden of cardiovascular disease in Europe.” The event, which drew more than 8,000 attendees, provided the opportunity for some of the top cardiologists and health professionals in the country to check their own PULS ratings.

Diethart Reichardt, Global Discovery Biosciences Managing Director for Germany commented, “Heart disease is an international disease and we believe the PULS Cardiac Test will significantly improve patient care in Germany.”

Heart disease remains the leading cause of death and disability worldwide, but is 80% preventable with early detection and lifestyle modifications. A major issue for physicians is being able to accurately detect the disease, since most patients present with no signs or symptoms before a fatal or debilitating heart attack.

The PULS Cardiac Test is a non-invasive blood test that measures the body’s immune response to coronary artery injury in patients with no symptoms of heart disease. The body’s response to coronary artery injury frequently causes formation of lesions in the coronary artery wall, which may become unstable and rupture, leading to the formation of a blood clot, the most common cause of heart attacks.

The test can predict the likelihood patients will experience an Acute Coronary Syndrome (ACS event) within a 5-year period – Identifying these vulnerable patients before they have a cardiac event guides physicians to improve patient care by allowing physicians to implement potentially life-saving prevention plans.

For more information and to request testing, visit .

About GD Biosciences

Global Discovery Biosciences (GD Biosciences) is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.

The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.

About the PULS Cardiac Test

The PULS Cardiac Test is a simple blood test that uses breakthrough medical technology to identify individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test uses 9 clinically-significant protein biomarkers to measure the body’s immune system response to arterial injury leading to the formation of unstable cardiac lesions – the cause of 75% of all Heart Attacks.

Check out our recent news coverage:
Fox News Special Report – Technology Helps Predict Heart Attacks
Travel Pulse – Could Blood Test Warn Pilots of Heart Attack Risk?
Times Colonist – Blood test can assess Heart Attack risk, conference told
Saskatoon Star Phoenix – New test for Heart Attack risk
The Province – Blood test can assess Heart Attack risk, Vancouver conference hears

Adam Farragut
PR Firm: The Publicity Agency
Phone: 813-708-1220 x7778

Direct link:

SOURCE:  GD Biosciences

This press release is distributed by PR NewsChannel. Your News. Everywhere.